Cantor Fitzgerald Comments on NBIX FY2026 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Neurocrine Biosciences in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn $6.53 per share for the year. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

A number of other brokerages have also commented on NBIX. Needham & Company LLC increased their price target on Neurocrine Biosciences from $138.00 to $139.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. Piper Sandler reaffirmed an "overweight" rating and issued a $154.00 price objective (down from $160.00) on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. HC Wainwright lowered their price objective on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a research note on Tuesday, April 22nd. BMO Capital Markets raised their price objective on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a research note on Tuesday, May 6th. Finally, Wall Street Zen lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 20th. Three investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $162.00.

Neurocrine Biosciences Stock Down 0.5%

Neurocrine Biosciences stock traded down $0.60 during midday trading on Tuesday, reaching $124.17. 916,917 shares of the stock traded hands, compared to its average volume of 1,142,148. The stock's fifty day moving average is $111.18 and its 200-day moving average is $121.93. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $157.98. The stock has a market cap of $12.29 billion, a P/E ratio of 37.74, a PEG ratio of 0.77 and a beta of 0.24.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The business had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. The business's revenue was up 11.1% on a year-over-year basis. During the same period last year, the company earned $1.20 EPS.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in NBIX. Golden State Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $25,000. Geneos Wealth Management Inc. increased its holdings in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock valued at $25,000 after purchasing an additional 135 shares during the last quarter. Huntington National Bank increased its holdings in shares of Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the last quarter. WPG Advisers LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at approximately $32,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at approximately $34,000. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the transaction, the director now owns 37,491 shares of the company's stock, valued at $4,131,508.20. This represents a 44.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kevin Charles Gorman sold 9,613 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total value of $1,157,212.94. Following the transaction, the director now directly owns 514,596 shares of the company's stock, valued at $61,947,066.48. The trade was a 1.83% decrease in their position. The disclosure for this sale can be found here. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences announced that its board has initiated a stock repurchase program on Friday, February 21st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.